Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1841830rdf:typepubmed:Citationlld:pubmed
pubmed-article:1841830lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:1841830lifeskim:mentionsumls-concept:C0021294lld:lifeskim
pubmed-article:1841830lifeskim:mentionsumls-concept:C0728731lld:lifeskim
pubmed-article:1841830lifeskim:mentionsumls-concept:C0085297lld:lifeskim
pubmed-article:1841830lifeskim:mentionsumls-concept:C0199176lld:lifeskim
pubmed-article:1841830pubmed:issue3-4lld:pubmed
pubmed-article:1841830pubmed:dateCreated1992-12-3lld:pubmed
pubmed-article:1841830pubmed:abstractTextImmunodeficiency, particularly antibody deficiency, is a crucial contributory factor to the increased susceptibility to infections in preterm infants. Availability of the recent preparation of intravenous immunoglobulin (ivIgG) led several authors to evaluate the safety and effectiveness of ivIgG for prophylaxis of infection in preterm infants. The results of these studies, although controversial, have pointed out two common findings: (1) ivIgG prophylaxis seems to be effective only in the very preterm infants, with mean birth weight below about 1,300 g: (2) ivIgG seems to be well tolerated by newborn infants.lld:pubmed
pubmed-article:1841830pubmed:languageenglld:pubmed
pubmed-article:1841830pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1841830pubmed:citationSubsetIMlld:pubmed
pubmed-article:1841830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1841830pubmed:statusMEDLINElld:pubmed
pubmed-article:1841830pubmed:issn0379-8305lld:pubmed
pubmed-article:1841830pubmed:authorpubmed-author:UgazioA GAGlld:pubmed
pubmed-article:1841830pubmed:authorpubmed-author:RondiniGGlld:pubmed
pubmed-article:1841830pubmed:authorpubmed-author:ChiricoGGlld:pubmed
pubmed-article:1841830pubmed:issnTypePrintlld:pubmed
pubmed-article:1841830pubmed:volume17lld:pubmed
pubmed-article:1841830pubmed:ownerNLMlld:pubmed
pubmed-article:1841830pubmed:authorsCompleteYlld:pubmed
pubmed-article:1841830pubmed:pagination144-9lld:pubmed
pubmed-article:1841830pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:meshHeadingpubmed-meshheading:1841830-...lld:pubmed
pubmed-article:1841830pubmed:year1991lld:pubmed
pubmed-article:1841830pubmed:articleTitleIntravenous immunoglobulin for prophylaxis of infection in preterm infants.lld:pubmed
pubmed-article:1841830pubmed:affiliationDivision of Neonatal Intensive Care, Policlinico San Matteo IRCCS, Pavia, Italy.lld:pubmed
pubmed-article:1841830pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1841830pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1841830pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1841830pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:1841830pubmed:publicationTypeReviewlld:pubmed